Skip to main content

$0.265 0.005 (1.92%)

High

$0.27

Low

$0.26

Trades

10

Turnover

$30,696

Volume

117,402
30 June 2023 at 3:52pm
Register to track EYE and receive email alerts.
Subject
EYE Ann: AlphaRet Investor Presentation

EYE Ann: 2RT Pivotal Study and Regulatory Pathway

EYE Ann: EYE Representative Appointed to American Glaucoma Society

EYE Ann: Notification regarding unquoted securities - EYE

EYE Ann: Investor presentation Half Year Results 31 December 2021

EYE Ann: Half year results discussion

EYE Ann: Half Yearly Report and Accounts

EYE Ann: Glaucoma Sales Update

EYE Ann: Reducing Progression Rate Age-Related Macular Degeneration

EYE Ann: Notification regarding unquoted securities - EYE

EYE Ann: Notification regarding unquoted securities - EYE

EYE Ann: Cancel - Proposed issue of securities - EYE

EYE Ann: Notification regarding unquoted securities - EYE

EYE Ann: Appendix 3Z Mr A Sundich

EYE Ann: AGM voting results

EYE Ann: EYE AGM Presentation

EYE Ann: AGM Withdrawal of AGM resolutions

EYE Ann: Resignation of Director

EYE Ann: Job Keeper Notice

EYE Ann: Update - Proposed issue of securities - EYE

EYE Ann: US Government Stimulus Loan Forgiven

EYE Ann: Notice of Annual General Meeting/Proxy Form

EYE Ann: 5 Year Efficacy of iTrack to be Spotlighted at ESCRS

EYE Ann: Date of AGM and Closing Date for Director Nominations

EYE Ann: Nova Eye to Present at ASX Small to Mid-Cap Conference

EYE Ann: Closure of Share Facility Unmarketable Parcels

EYE Ann: Application for quotation of securities - EYE

EYE Ann: Proposed issue of securities - EYE

EYE Ann: Aquisition of Glaucoma Patents

EYE Ann: Appendix 4G and Corporate Governance Statement

EYE Ann: FY21 Investor presentation

EYE Ann: Full Year Results FY21

EYE Ann: FY21 Appendix 4E and Annual Report

EYE Ann: Application for quotation of securities - EYE

EYE Ann: Proposed issue of securities - EYE

EYE Ann: Notice of Upcoming Investor Call - Full Year (FY21) Results

EYE Ann: Change in substantial holding from AEF

EYE Ann: FY21 Trading Update

EYE Ann: Shareholder letter holders of less than marketable Parcel

EYE Ann: Share Sale Facility for Less Than Marketable Parcels

EYE Ann: IDE Application for 2RT filed with the FDA

EYE Ann: 2RT to be Featured at the 2021 Meeting of ARVO

EYE Ann: Change in substantial holding from AEF

EYE Ann: First Patient enrolled in MAGIC Clinical Trial

EYE Ann: 2RT Post LEAD Review Shows Improved Treatment Benefits

EYE Ann: Clinical trial to Assess Efficacy and Safety of i Track

EYE Ann: Investor presentation Half year Results 31 December 2020

EYE Ann: Half Year Results Discussion

EYE Ann: Half Year Accounts

EYE Ann: Notice of Upcoming Investor Call

Register to track EYE and receive email alerts.

Similar Companies

AT1
COH
CSX
CYC
EMV
IBX
IPD
MX1
RSH
SOM